Navigation Links
Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries
Date:11/17/2009

HAYWARD, Calif., Nov. 17 /PRNewswire/ -- Zyomyx, Inc., a leader in chip-based bioanalysis technologies, today announced that its readerless CD4 point-of-care (POC) technology was selected by Imperial College London's CD4 Initiative as the best-performing POC test method for measuring CD4 T-cell count in HIV/AIDS patients. Zyomyx's CD4 assay is now the only remaining POC product being supported by the CD4 Initiative. With this announcement, Zyomyx is currently entering the commercial phase of this project and is actively soliciting partnerships with global sales and distribution providers.

Zyomyx has developed the world's first, fully quantitative CD4 readout in a POC format. As simple to read as a thermometer, Zyomyx's patent-pending assay uses CD4-binding reagents to pull CD4 cells from a blood sample and transfer them to a volumetric region of the device, where cell count can be determined by a simple visual readout. The quantitative CD4 count provides critical information in the clinical management of HIV. The test will give doctors and patients in resource-poor settings with limited infrastructure the same high-quality data that is available in the rest of the world.

The CD4 Initiative was established in 2005 by an initial award of $8.6 million from the Bill & Melinda Gates Foundation and is conducted under the aegis of the Imperial College London, UK. The Initiative's objective is to develop a low-cost, instrument-free test for measuring CD4 T-cells in HIV/AIDS patients. Throughout this year, the Initiative evaluated the three remaining systems using clinical samples. Prototypes were assessed against the predicate method of flow cytometry. Results from the verification trial showed that only Zyomyx's CD4 test compared favorably with those generated using the flow cytometry method.

"We are very pleased to confirm that the Zyomyx prototype not only meets the original specifications of the Initiative, but has in fact exceeded them," said Dr. Steven Reid, Project Manager of the CD4 Initiative from the Division of Medicine at Imperial College London. "While the original specification called for a simple cutoff test to determine whether to begin treatment, the Zyomyx approach will go much further by delivering a truly quantitative test which allows for both therapeutic monitoring as well as treatment decisions."

"There has been a lot of progress increasing access to life-saving HIV drugs in the developing world, but the lack of access to essential diagnostics like a CD4 test is a major barrier to providing the best possible care," said Dr. Hans-Georg Batz, Director and co-Founder of the CD4 Initiative. "Zyomyx's new test will have a huge impact for people living with HIV across the world. We are impressed by the innovation and fast pace of product development at Zyomyx, and we look forward to working with Zyomyx to finalize development and assist in getting their point-of-care tests into the hands of healthcare workers."

"As innovators in the field of bioanalysis platforms, Zyomyx set out to develop a point-of-care CD4 test that would arm healthcare workers with a key tool in managing patients in need of antiretroviral therapy. I commend our team for their hard work over the past few years, and also thank the members of the CD4 Initiative for supporting this important project and acknowledging and validating the Zyomyx approach," said Dr. Peter Wagner, President and CEO of Zyomyx, Inc. "Now that we have achieved this significant milestone, we are actively engaging with select global sales and distribution partners who can help us take the Zyomyx test to market. This includes additional cell count applications in diagnostics and life science research beyond CD4 where an inexpensive, simple alternative to flow cytometry is desired."

About Zyomyx

Zyomyx, Inc. is an innovator in bioanalysis platforms based on its expertise in assay development, surface chemistry, and microsystem technologies. The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the robust development of advanced but simple and inexpensive diagnostics such as the CD4 cell counting product.

Zyomyx is a privately held company and based in Hayward, Calif. For more information about Zyomyx, please visit www.zyomyx.com.

SOURCE Zyomyx, Inc.


'/>"/>
SOURCE Zyomyx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. mPay Gateway Teams With Allscripts to Provide Point-of-Care Patient Payment Tools to Physician Practices Nationwide
2. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
3. Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring
4. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
5. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
6. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
7. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
8. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
9. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
10. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
11. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):